Sumitomo Pharma Co., Ltd.: Sleep Initiation and Maintenance Disorders trials

The registry lists 11 Sleep Initiation and Maintenance Disorders studies with Sumitomo Pharma Co., Ltd. as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 3 9Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated InsomniaCompletedNCT00857220Phase 3Results posted
• Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated InsomniaCompletedNCT00856973Phase 3Results posted
• A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic InsomniaCompletedNCT00386334Phase 4Results posted
• Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With InsomniaCompletedNCT01710631Phase 3
• A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and InsomniaCompletedNCT00435279Phase 3
• Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving AbilityCompletedNCT00368056Phase 3
• A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive DisorderCompletedNCT00368030Phase 3
• Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid ArthritisCompletedNCT00367965Phase 3
• Study of Eszopiclone Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause/MenopauseCompletedNCT00366093Phase 3
• 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary InsomniaCompletedNCT00352144Phase 3
• Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety DisorderCompletedNCT00235508Phase 4